Intellia Adds Cardiomyopathy Patients to Existing Early-stage ATTR Study

https://www.fiercebiotech.com/biotech/jpm22-intellia-eye-to-bridgebio-s-phase-3-set-back-stacks-attr-trial-new-patient-group